Nilbax

Addressing implant-related infection
before it starts

TekCyte’s Nilbax passive surface coating forms a physical, drug-free barrier on devices to dramatically reduce bacterial adhesion and biofilm formation that can lead to implant-associated infections.

Surfaces that count, protection where it’s needed

Nilbax is ideal for high-risk devices where surface contamination poses a safety or performance threat:

Unsure if Nilbax is suitable for your product? Let’s evaluate it together.

A sustainable choice for modern medtech, implant fail

Nilbax is aligned with global sustainability frameworks and procurement standards, supporting:

With increasing regulatory and sustainability pressures across Europe and beyond, Nilbax helps manufacturers stay ahead of the curve without compromising patient safety or device performance.

TekCyte coatings are designed for manufacturers who want to lead in a market where safety, sustainability and regulatory alignment are essential.

Infection, implant failure and increased antibiotic use

THE PROBLEM

Infections associated with implanted medical devices are a major clinical and economic burden. Added to this, a large proportion of these infections are associated with a bacterial biofilm. Biofilm infections are difficult to treat with antibiotics, last longer, and can lead to long-term use of antibiotic therapy.

THE SOLUTION

Nilbax is a world-leading passive surface coating which forms a barrier that helps stop bacterial contamination and biofilms before they start. It is a drug-free, non-toxic and fully biocompatible coating, offering protection without using antibiotics or antimicrobial chemical agents, which are common in other coating products.

By preventing bacterial contamination and biofilm at the surface level, Nilbax aims to reduce the use for antibiotics and need for revision surgeries, supports improved patient outcomes, longer device life, and reduced risk of long-term complications.

Designed for performance, safety and scale

Passive coating technology

Nilbax does not rely on drug release or chemical leaching. Instead, it creates a stable, inert surface barrier that prevents contamination without introducing new toxicological risks. It is drug-free, non-toxic and biocompatible, offering protection without using antibiotics or antimicrobial chemical-based agents (common in other coating products).

Compatible with complex surfaces and sterilisation

Nilbax is engineered to perform across a wide range of medical-grade materials and device configurations. It can be applied to smooth, porous or 3D surfaces and remains stable under standard sterilisation methods. This flexibility allows Nilbax to support innovation without requiring manufacturers to compromise on device design or performance.

Biocompatibility you can trust

Nilbax has passed multiple Good Laboratory Practice (GLP) biocompatibility tests, including cytotoxicity, sensitisation, systemic toxicity and hemocompatibility studies. These internationally recognised tests help demonstrate that the coating is safe, well-tolerated, and suitable for use on medical devices. Meeting these standards is a critical step toward global regulatory approvals and commercial readiness.

Scalable and globally patent protection

Nilbax is supported by a robust international patent portfolio across the US, EU, China, India, Japan and Australia. The coating process is designed for scale – adaptable to both high and low-volume manufacturing environments. TekCyte works closely with commercial partners to integrate Nilbax into existing workflows, offering a seamless path from evaluation to full-scale rollout.

Successful Safety & Biocompatibility Tests

All studies showed no evidence of toxicity or sensitivity associated with exposure to Nilbax.

ISO Guinea Pig Maximization Sensitization Test
ISO Acute Systemic Toxicity Study in Mice
ISO Intracutaneous Irritation Study
Cytotoxicity Study Using the ISO Elution Method
ASTM Hemolysis Study

Designed for innovators, ready for market

If you’re creating next-generation devices and products and looking for a competitive edge, Nilbax offers a future-ready solution.

Evidence it Works

In vitro testing has shown that Nanovita reduces adhesion of various microorganisms leading to a reduction in formation of a biofilm on titanium surfaces.

Flexible Pathways to Commercial Integration

TekCyte works with companies that want to lead with proven surface technologies. We offer licensing and engagement pathways designed for innovators seeking to gain a competitive advantage.

We offer:

Join global innovators applying passive, drug-free coatings to the next generation of implants, instruments and industrial technologies.

Bringing Next-Generation Coatings to Market

Nanovita is part of TekCyte’s platform of innovative, passive surface technologies. With a strong IP portfolio, validated scientific performance, and flexible commercial pathways, TekCyte helps manufacturers meet today’s needs—and tomorrow’s demands.

Ready to learn more?